Opportunity Information: Apply for RFA PS 16 002
Apply for RFA PS 16 002
- The HHS-CDC-HHSCDCERA in the health sector is offering a public funding opportunity titled "Cohort Study to Assess Population Impact of Current and Evolving Chronic Viral Hepatitis Treatment" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.270,.
- This funding opportunity was created on Jan 13, 2016 and posted on Jan 13, 2016.
- Applicants must submit their applications by Mar 15, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Cohort Study to Assess Population Impact of Current and Evolving Chronic Viral Hepatitis Treatment" (Funding Opportunity Number RFA PS 16 002) is a CDC cooperative agreement focused on strengthening real-world, population-level evidence about chronic hepatitis B (HBV) and chronic hepatitis C (HCV) in the United States. The underlying public health need is substantial: the announcement cites an estimated 3.2 million people living with chronic HCV infection and about 1.25 million living with chronic HBV infection, with major mortality burdens each year (around 55,000 HCV-related deaths and roughly 2,000 to 4,000 HBV-related deaths). The opportunity is built on the idea that understanding these diseases and reducing their impact requires more than snapshots of prevalence or short clinical trials; it requires long-term follow-up of patients over time so researchers and public health agencies can observe the full spectrum of illness, progression, and outcomes in typical care settings.
At its core, this funding supports the development or continuation of longitudinal cohort data collection among people with chronic HBV and/or HCV. The CDC is looking for structured, ongoing observation of infected patients to better characterize natural history (how disease progresses in the absence of or alongside treatment), clinical outcomes, and broader public health consequences. A central emphasis is that treatment for viral hepatitis has been changing, and continues to evolve, so the cohort must be able to capture how current and emerging antiviral therapies perform outside of controlled trial environments. The purpose statement highlights several specific dimensions of interest: effectiveness (how well therapies work in routine practice), cost (economic implications of treatment and care), benefits (health improvements and avoided complications), and adverse effects (harms, side effects, and unintended consequences). Importantly, the announcement frames these questions at the population level, meaning the goal is not just to describe individual patient responses, but to estimate the broader impact of treatment strategies across communities and health systems.
The award mechanism is a cooperative agreement, which signals that CDC expects substantial involvement during the project rather than simply providing funds and receiving periodic reports. In many federal contexts, cooperative agreements imply closer collaboration on study design considerations, performance monitoring, and alignment with public health priorities, which fits a project aimed at generating actionable evidence for national hepatitis prevention and control efforts. The funding activity category is Health and the CFDA numbers listed are 93.270, reflecting the CDC assistance listing associated with this type of public health research and surveillance support.
Eligibility is broad and includes many types of organizations positioned to manage large-scale patient cohorts or access clinical populations. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education where specified); for-profit organizations (other than small businesses); small businesses; and other applicants as clarified in the opportunity materials. This wide eligibility reflects the reality that meaningful cohort work can be led by public health departments, academic medical centers, tribal health entities, integrated health systems, and other organizations with the infrastructure to recruit, follow, and analyze patient populations over time.
In terms of scale and competition, the notice lists an award ceiling of $500,000 and anticipates a single award (ExpectedAwards: 1). The opportunity was posted and created on January 13, 2016, with an original and current closing date of March 15, 2016. The sponsoring agency is HHS, specifically the CDC (HHS-CDC-HHSCDCERA). Taken together, this is a targeted, single-award investment intended to produce high-value longitudinal evidence about HBV and HCV treatment impacts, with the broader aim of informing public health decision-making, resource allocation, and strategies to reduce illness and death associated with chronic viral hepatitis.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Cohort Study to Assess Population Impact of Current and Evolving Chronic Viral Hepatitis Treatment."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA PS 16 002.
Which federal agency is sponsoring this opportunity?
The sponsoring department is HHS, and the sponsoring agency is the Centers for Disease Control and Prevention (CDC).
What type of award is this (grant vs. cooperative agreement)?
This opportunity is a CDC cooperative agreement. That means CDC expects substantial involvement in the project during the period of performance, rather than simply providing funds with limited interaction.
What is the main purpose of the cooperative agreement?
The main purpose is to strengthen real-world, population-level evidence about chronic hepatitis B (HBV) and chronic hepatitis C (HCV) in the United States by supporting the development or continuation of longitudinal cohort data collection among people with chronic HBV and/or HCV.
What public health need does this opportunity address?
The announcement describes a substantial public health burden, citing an estimated 3.2 million people living with chronic HCV infection and about 1.25 million people living with chronic HBV infection in the United States. It also cites major mortality burdens each year, including around 55,000 HCV-related deaths and roughly 2,000 to 4,000 HBV-related deaths.
What is meant by a "longitudinal cohort" in this funding context?
In this context, a longitudinal cohort refers to structured, ongoing observation and data collection from people with chronic HBV and/or HCV over time. The goal is to follow patients long-term to observe disease progression, outcomes, and the effects of treatment in typical care settings.
Why does CDC emphasize real-world, population-level evidence?
The opportunity is built on the idea that reducing the impact of HBV and HCV requires more than snapshots of prevalence or short clinical trials. Long-term follow-up in routine care settings helps characterize the full spectrum of illness, progression, and outcomes, and helps estimate how treatment strategies affect communities and health systems (not only individual patients).
What diseases or conditions are the focus of this opportunity?
The focus is chronic viral hepatitis, specifically chronic hepatitis B (HBV) and chronic hepatitis C (HCV).
Does the opportunity support work on HBV only, HCV only, or both?
The opportunity supports longitudinal cohort data collection among people with chronic HBV and/or chronic HCV, meaning the cohort may include HBV, HCV, or both.
What kinds of research or evaluation questions is the cohort expected to help answer?
The purpose statement highlights interest in understanding how current and emerging antiviral therapies perform outside controlled trial environments. Specific dimensions of interest include effectiveness (how well therapies work in routine practice), cost (economic implications of treatment and care), benefits (health improvements and avoided complications), and adverse effects (harms, side effects, and unintended consequences).
What does the opportunity mean by "natural history"?
"Natural history" refers to how chronic HBV or HCV progresses over time, including disease progression in the absence of treatment and how progression may look alongside treatment in real-world settings.
Why does the opportunity mention "current and evolving" treatments?
The announcement emphasizes that viral hepatitis treatment has been changing and continues to evolve. A longitudinal cohort is intended to capture the population impact of therapies that are currently used and those that emerge over time.
Is the goal to measure outcomes only at an individual patient level?
No. The announcement emphasizes population-level impact. While patient-level data are central to cohort follow-up, the stated goal is to estimate broader impacts of treatment strategies across communities and health systems.
What is the funding activity category?
The funding activity category is Health.
What CFDA number (assistance listing) is associated with this opportunity?
The CFDA number listed is 93.270.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include: state governments; county governments; city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education where specified); for-profit organizations (other than small businesses); small businesses; and other applicants as clarified in the opportunity materials.
Why is eligibility so broad for this opportunity?
The opportunity notes that meaningful cohort work can be led by a variety of organizations with access to clinical populations and the infrastructure to recruit, follow, and analyze patient populations over time. Examples implied by the announcement include public health departments, academic medical centers, tribal health entities, and integrated health systems.
How much funding is available per award?
The notice lists an award ceiling of $500,000.
How many awards does CDC expect to make?
The opportunity anticipates a single award (ExpectedAwards: 1).
When was the opportunity posted?
The opportunity was posted and created on January 13, 2016.
What is the application due date?
The original and current closing date listed is March 15, 2016.
What is the overall intent of the investment described in the notice?
The notice describes a targeted, single-award investment intended to produce high-value longitudinal evidence about HBV and HCV treatment impacts, with the broader aim of informing public health decision-making, resource allocation, and strategies to reduce illness and death associated with chronic viral hepatitis.
Does this opportunity explicitly tie the work to national hepatitis prevention and control efforts?
Yes. The cooperative agreement structure and the stated purpose indicate the evidence produced is intended to be actionable and aligned with public health priorities for hepatitis prevention and control.
Browse more opportunities from the same agency: HHS-CDC-HHSCDCERA
Browse more opportunities from the same category: Health
Next opportunity: NIDCD National Human Ear Tissue Laboratory Resource for Hearing and Balance Research (U24)
Previous opportunity: BLM NV 2016 Round 9 Lincoln County Archaeological Initiative Ely District Office
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA PS 16 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA PS 16 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDCD National Human Ear Tissue Laboratory Resource for Hearing and Balance Research (U24) Apply for RFA DC 17 001 Funding Number: RFA DC 17 001 Agency: HHS-NIH11 Category: Health Funding Amount: $475,000 |
| 2016 Cooperative Agreements to Benefit Homeless Individuals (Short Title: CABHI) Apply for SM 16 007 Funding Number: SM 16 007 Agency: HHS-SAMHS Category: Health Funding Amount: $1,500,000 |
| State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity and Associated Risk Factors and Promote School Health Apply for CDC RFA DP13 130504CONT16 Funding Number: CDC RFA DP13 130504CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Ryan White HIV/AIDS Program Part F Dental Reimbursement Program Apply for HRSA 16 089 Funding Number: HRSA 16 089 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Conducting Public Health Research in Kenya Apply for RFA GH 16 006 Funding Number: RFA GH 16 006 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: Case Dependent |
| Rural Health Research Center Cooperative Agreement Apply for HRSA 16 054 Funding Number: HRSA 16 054 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| International Bioethics Research Training Program (D43) Apply for PAR 16 082 Funding Number: PAR 16 082 Agency: HHS-NIH11 Category: Health Funding Amount: $230,000 |
| Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24) Apply for RFA RM 16 001 Funding Number: RFA RM 16 001 Agency: HHS-NIH11 Category: Health Funding Amount: $12,600,000 |
| Characterizing the Functional Elements in the Encyclopedia of DNA Elements (ENCODE) Catalog (UM1) Apply for RFA HG 16 003 Funding Number: RFA HG 16 003 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Early Comprehensive Childhood Systems Impact (ECCS Impact) Apply for HRSA 16 047 Funding Number: HRSA 16 047 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Computational Analysis of the Encyclopedia of DNA Elements (ENCODE) Data (U01) Apply for RFA HG 16 004 Funding Number: RFA HG 16 004 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIA Clinical Research Project Planning Grant Program (R34) Apply for PAR 16 085 Funding Number: PAR 16 085 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| ENCODE Data Analysis Center (U24) Apply for RFA HG 16 006 Funding Number: RFA HG 16 006 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Supporting Laboratory Strengthening Activities in Resource-Limited Countries under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1366SUPP15 Funding Number: CDC RFA GH13 1366SUPP15 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Integrated HIV Prevention and Health Services for Key and Priority Populations (HIS-KP) Apply for RFA 656 16 000001 Funding Number: RFA 656 16 000001 Agency: USAID-MOZ Category: Health Funding Amount: $20,000,000 |
| Evaluation of Core State Violence and Injury Prevention Program (Core SVIPP) Apply for CDC RFA CE16 1603 Funding Number: CDC RFA CE16 1603 Agency: HHS-CDC-NCIPC Category: Health Funding Amount: $300,000 |
| ENCODE Data Coordinating Center (U24) Apply for RFA HG 16 005 Funding Number: RFA HG 16 005 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Expanding the Encyclopedia of DNA Elements (ENCODE) in the Human and Mouse (UM1) Apply for RFA HG 16 002 Funding Number: RFA HG 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Population-based HIV Impact Assessments in Resource-Constrained Settings under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 140903CONT16 Funding Number: CDC RFA GH14 140903CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Implementing Evidence Based Prevention Intervention for Key Populations in the Republic of Rwanda under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 161602CONT16 Funding Number: CDC RFA GH15 161602CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA PS 16 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.